Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351936 · ClinicalTrials.gov registry record · Phase 4
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
A Phase 4 study, sponsored by North Suffolk Mental Health Association.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00351936 is a Phase 4 study that has completed, run by North Suffolk Mental Health Association. The registered enrollment target is 16 participants.
The verdict
NCT00351936, a Phase 4 study, has completed, sponsored by North Suffolk Mental Health Association.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective disorder. The advantage of the crossover design is that each subject will act as their own control and fewer subjects will be required than a between-group design.
Interventions
- DRUG placebo
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351936
The ClinicalTrials.gov registry entry for NCT00351936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Suffolk Mental Health Association, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00351936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351936 about?
NCT00351936 is a clinical study titled "A Placebo-Controlled, Cross-Over Trial of Aripiprazole". This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective disorder. The advantage of the crossover design is that each subject wil...
What is the current status of trial NCT00351936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00351936?
The interventions under investigation include: placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00351936?
This trial is sponsored by North Suffolk Mental Health Association, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.